| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | MADD |
| Uniprot No | Q8WXG6 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1409-1506aa |
| 氨基酸序列 | YSQQINEVLDQLANLNGRDLSIWSSGSRHMKKQTFVVHAGTDTNGDIFFMEVCDDCVVLRSNIGTVYERWWYEKLINMTYCPKTKVLCLWRRNGSETQ |
| 预测分子量 | 18.4 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于MADD(MAPK-activating death domain protein)重组蛋白的假设性参考文献示例(仅供参考，实际文献需通过学术数据库查询)：
---
1. **标题**：*Recombinant MADD Protein Enhances TNF-α-Induced Apoptosis in Cancer Cells*
**作者**：Chen L, et al.
**摘要**：研究利用大肠杆菌系统表达并纯化重组MADD蛋白，发现其通过激活JNK/p38信号通路增强肿瘤坏死因子-α(TNF-α)诱导的肿瘤细胞凋亡，为靶向治疗提供依据。
2. **标题**：*Structural and Functional Characterization of MADD Recombinant Protein in Neuronal Signaling*
**作者**：Patel R, et al.
**摘要**：通过哺乳动物细胞系统表达MADD重组蛋白，解析其与TrkA受体的相互作用，揭示其在神经生长因子(NGF)信号传导及神经元存活中的调控作用。
3. **标题**：*MADD Knockdown and Recombinant Protein Rescue in Metabolic Syndrome Models*
**作者**：Kim S, et al.
**摘要**：在代谢综合征细胞模型中，外源添加重组MADD蛋白可逆转胰岛素信号通路异常，表明MADD在糖代谢调控中的关键地位。
---
**提示**：实际文献可通过PubMed、Google Scholar等平台以关键词“MADD recombinant protein”、“IG20 expression”或“MAPK death domain recombinant”检索。部分相关研究可能聚焦于MADD的基因功能、信号通路或疾病关联。
**Background of MADD Recombinant Protein**
MADD (MAPK Activating Death Domain) is a multifunctional scaffold protein encoded by the *MADD* gene, located on human chromosome 11p11.2. Initially identified as a regulator of tumor necrosis factor (TNF) receptor-mediated apoptosis, MADD plays a critical role in intracellular signaling pathways, including MAPK (mitogen-activated protein kinase) and ERK (extracellular signal-regulated kinase) cascades. It interacts with death domain-containing receptors, such as TNF-R1. modulating cell survival, proliferation, and stress responses.
Structurally, MADD contains a death domain, which facilitates protein-protein interactions, and a guanine nucleotide exchange factor (GEF) domain, involved in Rab3 GTPase activation—a key process in vesicular trafficking and neurotransmitter or hormone secretion. Dysregulation of MADD has been linked to several diseases, including type 2 diabetes, Parkinson’s disease, and cancers, highlighting its therapeutic potential.
Recombinant MADD protein is produced using expression systems like *E. coli* or mammalian cells, enabling large-scale, high-purity yields for research and drug development. Its recombinant form allows detailed study of molecular mechanisms, such as insulin secretion defects in diabetes or dopaminergic neuron degeneration in Parkinson’s. Additionally, MADD serves as a tool for screening inhibitors or agonists targeting related pathways.
By leveraging recombinant MADD, researchers aim to unravel its dual roles in cell death and survival signaling, paving the way for novel diagnostic or therapeutic strategies in metabolic and neurodegenerative disorders.
×
